July 15, 2020
I oppose reducing the reporting requirements.
Markets get more efficient with more information, not less.
The burden of sharing this information is worth the price for a transparent market.
I am an investor and a director of a growing biotech company. I both understand the burden of the disclosures for the companies and the benefits of the information as an investor.
The difference is one of a nuisance for the company but an fundamental risk for the economy.
I strongly oppose these changes.